In 1984, I wrote my first prescription for the antimalarial drug, hydroxychloroquine (Plaquenil), for a 28-year-old woman with SLE. She was considerably overweight, with inflammatory arthritis and a photosensitive rash, and I worried that oral corticosteroids would tip her over into diabetes. I presented the case to my attending, Steven Malawista, MD, at the Yale…
New research compares pathogenic immune response in SLE with immune response that contributes to atherosclerotic plaque
Case report highlights important twist to differential diagnosis of neuropsychiatric lupus
Better understanding of kidney inflammation and fibrosis in LN, along with finding novel disease biomarkers could help rheumatologists gauge patients’ response to therapy
Nurses’ cohort of 38 years provides wealth of patient information, research for rheumatologists
Proper coding for cases of drug-induced gout, systemic lupus erythematosus with lung involvement, inflammatory rheumatoid arthritis, osteoporosis
Coding cases of drug-induced gout, systemic lupus erythematosus with lung involvement, inflammatory rheumatoid arthritis, osteoporosis
Rheumatology experts review history of LN, offer explanations for roadblocks to better therapies
Foundation appeals to Congressional lawmakers for support of biomedical innovation to battle lupus
Information technology an overarching theme of this year’s work